About Us

Mission

Bio-Converts mission is to develop the preferred treatment for oral leukoplakia. Our innovative therapeutic agent, QR-2, uses a novel drug delivery technology, that enables more precise, effective and efficient treatment.

Vision

Bio-Converts visions is to revolutionize the treatment of oral leukoplakia, with our unique QR-2 patch. Aimed at minimizing or remove oral leukoplakia lesions, that further reduces the risk of patients developing oral cancer from it.

Background

Oral leukoplakia is a potentially cancerous white patch or plaque in the mouth, strongly linked to smoking. The edges of the lesion are typically abrupt and the lesion changes. Oral leukoplakia also has dysplasia which highlights the severity of the disorder and is a marker of disease progression. Dysplasia is abnormal cell growth, a precancerous condition more serious than normal cell overgrowth (hyperplasia). In adults, precancerous dysplasia may not always turn into cancer, but there's a risk it could.Bio-Convert have identified a novel drug delivery technology, that we believe holds significant potential to become the preferred future treatment of oral leukoplakia (OL) using our unique patch, QR-2. The patch is applied directly to the lesions in the mouth. The treatment is intended to reduce/remove the OL lesions, and it will facilitate surgical procedure and improve, and reduce the malign conversion rate, lowering the risk of them turning into cancer.

Business Model

Bio-Convert is committed to developing a treatment for oral leukoplakia based on a novel drug delivery technology, that we believe holds significant potential to become a preferred method of treatment in the future.

Bio-Convert’s process:

  • Enter into contracts with reputable partners possessing the appropriate technology to conduct clinical trials.
  • Formulation development.
  • Conduct pre-clinical tests.
  • Submit global patent applications.
  • Commence the initial clinical Proof of Concept (POC) study.
  • The anticipated timeline for advancing the development project is approx. 24 months, starting in November 2023.

Strategy

Bio-Converts developmental strategy consists of: Using a proprietary patch formulation developed by university of Copenhagen consisting of three layers with long patent life, with 5-FU being added to the patch. 5-flouracil will be used as active ingredient and is administered on daily for 12 weeks. Enroll patients with moderate to severe dysplasia in the study. Once the prototype and final formulation are tested in a phase IA, including local tolerability, the product is ready, and evaluating for tolerability and preliminary efficacy will be initiated.

Management Team

Allan Wehnert

CEO & Founder

Mr. Wehnert has over 30 years in the pharmaceutical industry, specializing in discovering and developing new molecules for central nervous system disease treatment. A trained pharmacologist, he’s authored 25 scientific papers in prestigious international journals. Currently, as Initiator Pharma’s Senior VP for Research and Development, he advises private equity syndicates and owns Decision Insights.

During his 25-year tenure as Senior VP at Lundbeck, Allan led drug development from pre-clinical stages to NDA/EMA approval. He played a key role in bringing 6 products to market and overseeing over 75 due diligence processes, along with more than 7 asset and company acquisitions.




Board of Directors

Christian Hill Madsen – Chairman

Mr. Hill-Madsen has more than 25 years of experience working as a headhunter dedicated to the Life Science Industry in the Nordics, mastering the fine art of finding the best candidates for the right job, in all aspects of the healthcare solution program from Headhunting and Recruitment, Salesforce Optimization, Assessment to Organizational Development. Etc. Mr. Hill-Madsen is one of the few headhunters truly dedicated to the Life Science industry – from the single objective of wanting to be the best of what he does, working with his clients in the full employee life cycle to ensure that his clients always have the right person serving in the right position. Mr. Hill-Madsen is currently the founder and CEO of the Life Science headhunting firm, Hill-Consult, as well as being the founder and CEO of the Life Science advisory firm Nordicare Danmark, and Chairman of the Board of Directors of the Life Science venture holding company, NORDICUS Partners Corporation

Samia Sofie Kappe – Member

Mrs. Kappe holds a Master of Science in International Management and Marketing from Copenhagen University from 2001 and a SIMI MBA program in Managing Medical Product Innovations from 2006. Mrs. Kappe joined Novo Nordisk Pharmatech A/S in 2022 as CCO and Director of Sales and Marketing. For more than 20 years, she has taken up regional and global commercial responsibility and held various leadership positions in the pharmaceutical industry, covering sales, marketing, business development, scientific documentation, supply chain, R&D, manufacturing and quality. Prior joining Novo Nordisk Pharmatech A/S, Mrs. Kappe was heading up a CDMO owned by Orifarm, and prior to that, she worked for companies like Lundbeck, Leo Pharma and Coloplast.

Allan Wehnert – CEO, Founder and Member

Mr. Wehnert has over 30 years in the pharmaceutical industry, specializing in discovering and developing new molecules for central nervous system disease treatment. A trained pharmacologist, he's authored 25 scientific papers in prestigious international journals. Currently, as Initiator Pharma's Senior VP for Research and Development, he advises private equity syndicates and owns Decision Insights. During his 25-year tenure as Senior VP at Lundbeck, Allan led drug development from pre-clinical stages to NDA/EMA approval. He played a key role in bringing 6 products to market and overseeing over 75 due diligence processes, along with more than 7 asset and company acquisitions.